M a i n r e s u l t s
Overall, fewer blacks than nonblacks had the composite endpoint (9.7% vs 12.3%), combined CHD (15.9% vs 22.5%), and combined CVD (28.4% vs 33.7%) (P for all interactions < 0.001). Blacks had higher rates of stroke (6.5% vs 5.3%, P < 0.001), endstage renal disease (2.6% vs 1.5%, P < 0.001), and overall mortality (17.7% vs 16.8%, P = 0.003) than nonblacks. The 3 treatment groups did not differ for the composite endpoint in either racial subgroup (Table) . In blacks or nonblacks, no difference was found between amlodipine and chlorthalidone for any secondary outcomes except for HF ( 
C o n c l u s i o n s
In black or nonblack patients with hypertension, amlodipine or lisinopril was not better than chlorthalidone for reducing cardiovascular disease. Chlorthalidone was associated with a lower risk for heart failure than amlodipine or linisopril in either racial subgroup. 
C o m m e n t a r y
In this planned substudy of the ALLHAT trial (1), Wright and colleagues examined whether CVD outcomes differed between black and nonblack patients who were started on 1 of 3 different classes of antihypertensive agents. Confirming the main trial's results, initial treatment with either amlodipine or lisinopril was not found to be superior to chlorthalidone in either racial group. In blacks, blood pressure (BP) was lowered by all 3 drugs, although less so by lisinopril, as patients on this drug had final systolic BP readings 5 mm Hg higher than in the other groups. This is congruent with other research suggesting reduced responsiveness to angiotensin-converting enzyme (ACE) inhibitors among blacks (2) . In this trial, black patients in the lisinopril group had increased rates of stroke, CHD, and combined CVD. Because lisinopril did not lower BP as much, it is uncertain if lisinopril's worse CVD outcomes were simply caused by ineffective BP control or some ACE inhibitor-related effect.
Despite equivalent BP lowering in patients treated with amlodipine and chlorthalidone, fewer patients of either race developed HF while taking chlorthalidone. Other CV endpoints were equivalent. These data do not support the view that amlodipine is more effective in patients of either race. These results bolster the recommendation of the Joint National Committee 7, which states that thiazide diuretics be the first-line antihypertensive choice for most patients (3), including blacks and nonblacks.
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